$10.52
0.38% today
Nasdaq, Sep 24, 07:18 pm CET
ISIN
US68622P1093
Symbol
ORIC

ORIC Pharmaceuticals Inc Stock price

$10.48
+0.86 8.94% 1M
+3.11 42.20% 6M
+2.41 29.86% YTD
-0.25 2.33% 1Y
+7.08 208.24% 3Y
-9.52 47.60% 5Y
-15.29 59.33% 10Y
-15.29 59.33% 20Y
Nasdaq, Closing price Tue, Sep 23 2025
-0.34 3.14%
ISIN
US68622P1093
Symbol
ORIC
Industry

Key metrics

Basic
Market capitalization
$1.0b
Enterprise Value
$735.3m
Net debt
positive
Cash
$282.5m
Shares outstanding
86.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
3.1
Financial Health
Equity Ratio
88.7%
Return on Equity
-52.7%
ROCE
-45.6%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-148.8m | $-145.3m
EBIT
$-150.0m | $-150.6m
Net Income
$-137.0m | $-149.4m
Free Cash Flow
$-121.1m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-20.0% | -2.4%
EBIT
-19.9% | -5.4%
Net Income
-23.6% | -16.7%
Free Cash Flow
-20.4%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.8
FCF per Share
$-1.4
Short interest
8.5%
Employees
115
Rev per Employee
$0.0
Show more

Is ORIC Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,013 stocks worldwide.

ORIC Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a ORIC Pharmaceuticals Inc forecast:

17x Buy
94%
1x Hold
6%

Analyst Opinions

18 Analysts have issued a ORIC Pharmaceuticals Inc forecast:

Buy
94%
Hold
6%

Financial data from ORIC Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 31 31
15% 15%
-
- Research and Development Expense 118 118
21% 21%
-
-149 -149
20% 20%
-
- Depreciation and Amortization 1.19 1.19
13% 13%
-
EBIT (Operating Income) EBIT -150 -150
20% 20%
-
Net Profit -137 -137
24% 24%
-

In millions USD.

Don't miss a Thing! We will send you all news about ORIC Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ORIC Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
19 days ago
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on September 2, 2025 (the “Grant Date”), ORIC granted a total of 292,500 non-qualified stock options and 79,000 restricted stock units to ...
Neutral
Seeking Alpha
21 days ago
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC ) Pharmaceuticals, Inc. Citi's Biopharma Back to School Conference September 3, 2025 4:00 PM EDT Company Participants Jacob Chacko - President, CEO & Director Dominic Piscitelli - Chief Financial Officer Conference Call Participants Yigal Nochomovitz - Citigroup Inc., Research Division Presentation Yigal Nochomovitz Director and SMid Cap Biotech Analyst W...
Neutral
GlobeNewsWire
28 days ago
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will be participating in the following investor conferences in September:
More ORIC Pharmaceuticals Inc News

Company Profile

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.

Head office United States
CEO Jacob Chacko
Employees 115
Founded 2014
Website oricpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today